OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Ming Yi, Mengke Niu, Yuze Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 100

Showing 26-50 of 100 citing articles:

STING in Cancer Immunoediting: Modeling Tumor-Immune Dynamics Throughout Cancer Development
Xiao Zhang, Yan Chen, Xi Liu, et al.
Cancer Letters (2025) Vol. 612, pp. 217410-217410
Open Access | Times Cited: 1

Regulation of cGAS-STING signalling in cancer: Approach for combination therapy
Hitesh Vasiyani, Bhumika Wadhwa, Rajesh Singh
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188896-188896
Closed Access | Times Cited: 20

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Tianye Li, Xinrun Wang, Mengke Niu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20

STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs)
Jiale Liu, Chenmian Liu, Yana Ma, et al.
Cancer Letters (2024) Vol. 588, pp. 216700-216700
Open Access | Times Cited: 7

Manganese-coordinated nanoparticle with high drug-loading capacity and synergistic photo-/immuno-therapy for cancer treatments
Han Chen, Haijing Qu, Yuqing Pan, et al.
Biomaterials (2024) Vol. 312, pp. 122745-122745
Closed Access | Times Cited: 7

Components, Formulations, Deliveries, and Combinations of Tumor Vaccines
Tengfei Liu, Wenyan Yao, Wenyu Sun, et al.
ACS Nano (2024) Vol. 18, Iss. 29, pp. 18801-18833
Closed Access | Times Cited: 6

Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer
Ping Yu, Yaru Wang, Dahai Yuan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15

cGAS-STING at the crossroads in cancer therapy
Rui Wang, Aashiq Hussain, Guo Quanquan, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104194-104194
Closed Access | Times Cited: 15

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
Xiaohan Guo, Yi Wu, Xue Ying, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13

Nanoformulations of chemotherapeutic activators of the cGAS–STING pathway in tumor chemoimmunotherapy
Lingzhi Wang, Zhuo Yu, Jihong Zhang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103892-103892
Closed Access | Times Cited: 5

Advances in reprogramming of energy metabolism in tumor T cells
Liu Xuekai, Yan Song, Jian Chu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5

RNA epigenetics in pulmonary diseases: Insights into methylation modification of lncRNAs in lung cancer
Junjie Jiang, Minghao Duan, Zheng Wang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116704-116704
Open Access | Times Cited: 5

Self‐Oxygenated Hydrogel Enhances Immune Cell Response and Infiltration Via Triggering Dual DNA Damage to Activate cGAS‐STING and Inhibiting CAFs
Huiting Tian, Nan Zhu, Haiting Wang, et al.
Small (2024) Vol. 20, Iss. 45
Closed Access | Times Cited: 5

T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma
Robin Reschke, Alexander Enk, Jessica C. Hassel
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1046-1046
Open Access | Times Cited: 5

In virto priming of the STING signaling pathway enhances the maturation and activation of dendritic cells induced by hepatitis B vaccine
Chaomin Ren, Xufeng Cui, Hui‐Xin Wang, et al.
Immunology Letters (2025) Vol. 272, pp. 106977-106977
Closed Access

Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy
R R Zhao, Xing-Xing Fan
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1440-1440
Open Access

Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy
Huan Song, Lin Chen, Xuanxuan Pan, et al.
Cancer Cell (2025) Vol. 43, Iss. 3, pp. 503-518.e10
Open Access

Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access

STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
Laura Gehrcken, Christophe Deben, Evelien Smits, et al.
Advanced Science (2025)
Open Access

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
Muyesar Alifu, Min Tao, Xiao Chen, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11

Second messenger 2'3'-cyclic GMP-AMP (2'3'-cGAMP): the cell autonomous and non-autonomous roles in cancer progression
Xiaoyu Ma, Man Chen, Linghua Meng
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 5, pp. 890-899
Closed Access | Times Cited: 4

Tissue biomarkers of immune checkpoint inhibitor therapy
Fatemeh Davoudi, Afshin Moradi, Habib Sadeghirad, et al.
Immunology and Cell Biology (2024) Vol. 102, Iss. 3, pp. 179-193
Open Access | Times Cited: 4

Scroll to top